Incidence and Risk of Venous Thromboembolism in Bisphosphonates and Selective Estrogen Receptor Modulators Treatment in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park So Young | - |
dc.contributor.author | Kim Se Hwa | - |
dc.contributor.author | Kim Tae-Young | - |
dc.contributor.author | Lee Young-Kyun | - |
dc.contributor.author | Ha Yong-Chan | - |
dc.contributor.author | Jang Sunmee | - |
dc.contributor.author | Ahn Seong Hee | - |
dc.contributor.author | Kim Ha Young | - |
dc.date.accessioned | 2021-07-24T14:40:56Z | - |
dc.date.available | 2021-07-24T14:40:56Z | - |
dc.date.created | 2021-07-12 | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81748 | - |
dc.description.abstract | Background: Selective estrogen receptor modulators (SERMs) were associated with an increased risk of venous thromboembolism (VTE) due to the estrogen effect. In this study, we investigated the effect of SERMs on VTE compared to bisphosphonates (BPs) using the Korean National Health Insurance claims database. Methods: This was a retrospective cohort study. Women over 50 years old who were first prescribed BPs or SERMs for osteoporosis treatment in 2012 were included. The difference in VTE incidence between the SERMs and BP groups was compared. Both groups were followed up for VTE or PE occurrence, death, or until December 2016. The study population was analyzed by 3:1 matching according to age using a multivariate Cox model. Results: The hazard ratio (HR) for VTE was 0.72 (95% confidence interval [CI], 0.40–1.28) in the SERMs group compared to BP group. Older age (60–69 vs. 50–59 years: HR, 3.77; 95% CI, 2.07–6.86 and 70–79 vs. 50–59 years: HR, 5.88; 95% CI, 3.14–11.02), major osteoporotic fracture (HR, 1.77; 95% CI, 1.16- 2.70), atrial fibrillation (HR, 3.31; 95% CI, 1.35–8.11), and estrogen replacement (HR, 3.40; 95% CI, 2.01–5.73) all increased VTE risk. In subgroup analysis of the SERMs group, past hospitalization (HR, 2.24; 95% CI, 1.02–4.92), estrogen replacement (HR, 5.75; 95% CI, 2.29–14.39), and glucocorticoid replacement (HR, 2.71; 95% CI, 1.05–7.0) increased VTE risk. Conclusion: SERMs did not increase the risk of VTE compared to BPs in Koreans with osteoporosis. However, old age and estrogen replacement both increased VTE risk. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한의학회 | - |
dc.relation.isPartOf | Journal of Korean Medical Science | - |
dc.title | Incidence and Risk of Venous Thromboembolism in Bisphosphonates and Selective Estrogen Receptor Modulators Treatment in Korea | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000672677000003 | - |
dc.identifier.doi | 10.3346/jkms.2021.36.e186 | - |
dc.identifier.bibliographicCitation | Journal of Korean Medical Science, v.36, no.27, pp.1 - 10 | - |
dc.identifier.kciid | ART002737756 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85110771819 | - |
dc.citation.endPage | 10 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | Journal of Korean Medical Science | - |
dc.citation.volume | 36 | - |
dc.citation.number | 27 | - |
dc.contributor.affiliatedAuthor | Jang Sunmee | - |
dc.subject.keywordAuthor | Selective Estrogen Receptor Modulators | - |
dc.subject.keywordAuthor | Bisphosphonate | - |
dc.subject.keywordAuthor | Osteoporosis | - |
dc.subject.keywordAuthor | Venous Thromboembolism | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.